Candidiasis, Invasive clinical trials
The registry lists 65 studies for Candidiasis, Invasive across more than 10 countries. 6 are recruiting or about to start. 35 of them are mainly about Candidiasis, Invasive (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-30. Counting its narrower condition Candidemia too: 109 studies, 9 open.
Get an email when these change. Save the Candidiasis, Invasive studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Pfizer (9) · Astellas Pharma Inc (4) · Scynexis, Inc. (4) · Merck Sharp & Dohme LLC (4) · University Medical Center Groningen (3) · Basilea Pharmaceutica (2) · Duke University (2) · Cidara Therapeutics Inc. (2)
What is being tested here
Drugs under test in Candidiasis, Invasive studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Who these studies take
Of the 5 Candidiasis, Invasive studies recruiting now, 5 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 3 (60%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (60%) | 3 (60%) |
| 18 | 5 (100%) | 5 (100%) |
| 30 | 5 (100%) | 5 (100%) |
| 40 | 5 (100%) | 5 (100%) |
| 50 | 5 (100%) | 5 (100%) |
| 65 | 5 (100%) | 5 (100%) |
| 75 | 5 (100%) | 5 (100%) |
| 85 | 5 (100%) | 5 (100%) |
Across all 65 studies, recruiting or not: 18% stop at 75 or younger and 18% at 65; 29% take children; 2% are for women only and 0% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 65. Browse all 65 → or search them.
- Comparison of Uncomplicated Candidemia Therapy Duration in Children and AdultsRecruitingNCT05763251Not applicable2 countries
- A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.RecruitingNCT05421858Phase 320 countries
- Shortening Treatment Duration in Uncomplicated Candidemia: the CanTEN TrialNot yet recruitingNCT07788586Phase 41 country
- Invasive Candidiasis in Critical CareRecruitingNCT064561511 country
- Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell TransplantsRecruitingNCT03717623Phase 41 country
- ECMM Candida Registry - CandiRegRecruitingNCT034500051 country
- A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive CandidiasisCompletedNCT06194201Phase 21 country
- A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral FluconazoleTerminatedNCT05178862Phase 313 countries
- Early Discontinuation of Empirical Antifungal Therapy and BiomarkersCompletedNCT03538912Not applicable1 country
- Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow TransplantationCompletedNCT04368559Phase 39 countries
- Non-Conventional Microbiological Methods in the Diagnosis of CandidemiaCompletedNCT07422155Not applicable1 country
- Phylogenetic Characteristics of Different Candida Species and Their Impact on the Clinical Picture of Patients With Invasive Candidiasis. What Has Changed During the COVID Pandemic?WithdrawnNCT074221941 country
- Pharmacokinetics of Micafungin in Patients of Intensive Care UnitsCompletedNCT02164890Phase 41 country
- An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida AurisCompletedNCT04148287Phase 21 country
- A Study of ABCD for Injection in Subjects With Invasive Candidiasis and Invasive AspergillusCompletedNCT05707832Phase 31 country
- Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida InfectionsCompletedNCT00413218Phase 325 countries
- Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal TreatmentCompletedNCT03059992Phase 38 countries
- Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida MeningitisCompletedNCT03421002Phase 21 country
- Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the DrugCompletedNCT00608335Phase 12 countries
- Non-interventional Study for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania - ERADICATE StudyCompletedNCT031744575 countries
- A B-D-Glucan Driven Antifungal Stewardship Approach for Invasive CandidiasisTerminatedNCT03090334Not applicable1 country
- Clinical Study to Evaluate the Efficacy of an Anti-Fungal SupplementCompletedNCT06146504Not applicable1 country
- Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)CompletedNCT03363841Phase 34 countries
- Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive CandidiasisCompletedNCT02244606Phase 25 countries
- Evaluate the Performance of Genetic Amplification by Polymerase Chain Reaction (PCR) and the "Mannan Antigenemia and Antimannan Antibodies Couple as a Means of Diagnosis and a Marker of Follow-up in Invasive Candidiasis.CompletedNCT023334481 country
- Early Identification of Candida in Intra-abdominal CandidiasisCompletedNCT052645711 country
- Efficacy of Prophylactic Fluconazole Therapy in Preterm and Very Low Birth Weight Neonates in Preventing Invasive Fungal Infection.CompletedNCT05848492Phase 31 country
- Peritoneal 1.3-ß-D-glucan for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients (pBDG2)CompletedNCT039979291 country
- Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive CandidiasisCompletedNCT03667690Phase 318 countries
- Evaluate Bioequivalence of Micafungin (50mg/Vial)CompletedNCT05496725Phase 41 country
- BIOPIC: Fungal Biomarkers for Diagnosis and Response to Therapy for Pediatric CandidemiaCompletedNCT022207904 countries
- NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida SepsisCompletedNCT028016821 country
- Comparison of Two Diagnostic Tests in Patients With Suspected Invasive Candidiasis in Internal Medicine Wards and Who Are Currently Timely Treated With MicafunginTerminatedNCT03906916Phase 41 country
- Genetic Susceptibility Factors for Candidemia.CompletedNCT028415011 country
- CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging ExtensionCompletedNCT02734862Phase 210 countries
- Amphotericin B Cholesteryl Sulfate Complex for Injection(ABCD) in the Treatment of Invasive Candidiasis and Invasive AspergillosisStatus unknownNCT04225195Phase 2
- Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)TerminatedNCT01945281Phase 2
- Pharmacokinetics of Micafungin in Children on Extracorporeal Membrane OxygenationCompletedNCT01666769Phase 11 country
- Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive CandidiasisCompletedNCT00761267Phase 310 countries
- Influence of Open and Laparoscopic Abdominal Surgery Involving the Intestinal Tract on Serum 1,3-ß-D-Glucan (BDG) ValuesCompletedNCT03468803Not applicable1 country
- A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)CompletedNCT01165320Phase 2
- Invasive Candidiasis in Saudi ICUsCompletedNCT014906841 country
- Variability of Fluconazole Concentration in Critically Ill PatientsCompletedNCT024911511 country
- A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)CompletedNCT00250432Phase 3
- Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067)TerminatedNCT01045798Phase 2
- Pharmacokinetics of Micafungin in Critically Ill PatientsCompletedNCT017169881 country
- Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With EchinocandinsTerminatedNCT01213823
- Candida Spp. in the Lower Respiratory Tract: Harmless Residents or Pathogen?CompletedNCT007869031 country
- Empirical Antifungal Treatment in ICUSCompletedNCT01773876Phase 31 country
- β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) PatientsCompletedNCT00672841Not applicable1 country